Allergic Rhino-Conjunctivitis - Market Insight, Epidemiology, and Market Forecast - 2036

Key Highlights:

• The allergic rhinoconjunctivitis market is anticipated to sustain a steady Compound Annual Growth Rate (CAGR) during the forecast period (2026-2036). This growth in market revenue is primarily propelled by a rising global prevalence of allergic rhinoconjunctivitis affecting over 400 million people worldwide, increasing environmental allergen exposure, growing urbanization and pollution levels, expanding adoption of targeted biologics and allergen immunotherapy, and increased R&D investment in novel treatment approaches including anti-IgE monoclonal antibodies, anti-IL-4/IL-13 biologics, and sublingual immunotherapy.
• The increasing cases of allergic rhinoconjunctivitis may be attributed to a combination of factors, including rising prevalence of IgE-mediated type I hypersensitivity reactions, climate change extending pollen seasons, growing exposure to indoor allergens such as house dust mites and pet dander, and increasing comorbid conditions including asthma, atopic dermatitis, sinusitis, and ocular conjunctivitis - all of which amplify disease burden and complicate disease management.
• Mixed Pollens Allergen Extract (ORALAIR) by Stallergenes Greer and House Dust Mite Allergen Extract (ODACTRA) by ALK-Abello exemplify the growing role of allergen immunotherapy in allergic rhinoconjunctivitis management. ORALAIR, is designed to induce long-term immune tolerance in patients with grass pollen-induced allergic rhinoconjunctivitis, while ODACTRA targets house dust mite-induced allergic rhinitis with or without conjunctivitis through disease-modifying sublingual immunotherapy. Together, these therapies reflect the shift beyond symptomatic treatment toward allergen-specific interventions capable of addressing the underlying immunologic drivers of disease and potentially providing sustained clinical benefit.
• A gap remains for a single intervention that delivers both rapid and durable long-term symptom control across the full spectrum of allergic rhinoconjunctivitis - encompassing nasal congestion, sneezing, rhinorrhea, and ocular symptoms - while demonstrating disease-modifying activity, safety across pediatric and adult populations, and minimal systemic adverse effects beyond the current standard of care.
• The future market for Allergic Rhinoconjunctivitis will be highly competitive, with multiple entrants -MM09-MG01 (Inmunotek) in Phase III subcutaneous immunotherapy for rhinoconjunctivitis triggered by house dust mites - advancing through clinical development. As these therapies gain approval, market dynamics are set to intensify and overall growth is projected to accelerate at a significant CAGR.

DelveInsight's comprehensive report titled "Allergic Rhinoconjunctivitis - Market Insights, Epidemiology, and Market Forecast - 2036" offers a detailed analysis of allergic rhinoconjunctivitis across its seasonal and perennial subtypes and associated comorbid conditions. The report presents historical and projected epidemiological data covering total prevalent cases of allergic rhinoconjunctivitis, total diagnosed prevalent cases of allergic rhinoconjunctivitis, comorbidity-associated cases of allergic rhinoconjunctivitis - including cases co-existing with asthma, atopic dermatitis, and sinusitis - subtype-specific cases of allergic rhinoconjunctivitis, and treated cases of allergic rhinoconjunctivitis. In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2026 to 2036.

The report analyzes the existing treatment practices and unmet medical requirements in Allergic Rhinoconjunctivitis. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.

Allergic Rhinoconjunctivitis Understanding and Treatment Algorithm

Allergic Rhinoconjunctivitis Overview and Diagnosis

Allergic rhinoconjunctivitis is a chronic, IgE-mediated inflammatory disorder characterized by concurrent inflammation of the nasal mucosa and conjunctiva following exposure to airborne allergens. Clinical manifestations are driven by mast cell activation and the release of inflammatory mediators, including histamine, leukotrienes, and cytokines, resulting in vasodilation, sensory nerve stimulation, mucus hypersecretion, and increased lacrimation. The condition is commonly classified into seasonal allergic rhinoconjunctivitis (SARC), often referred to as hay fever and triggered by seasonal outdoor allergens such as grass and tree pollens, and perennial allergic rhinoconjunctivitis (PARC), which is associated with year-round exposure to indoor allergens such as house dust mites and pet dander. Seasonal disease is frequently diagnosed during childhood and adolescence, whereas perennial disease is often linked to chronic indoor allergen exposure throughout adulthood.

The diagnostic workup typically begins with a detailed clinical history and physical examination, with diagnosis primarily based on symptom patterns, allergen exposure history, and confirmatory allergy testing. Skin prick testing (SPT) remains the preferred first-line method for detecting allergen-specific IgE sensitization, while serum-specific IgE testing serves as a valuable alternative when SPT is unavailable or contraindicated. Nasal cytology may be used as a complementary tool to differentiate allergic from non-allergic rhinitis and to identify local allergic rhinitis (LAR), a phenotype characterized by symptoms consistent with allergic rhinoconjunctivitis despite negative skin prick and serum-specific IgE test results. In such cases, the nasal provocation test (NPT) is considered the diagnostic gold standard for confirming local allergic rhinitis.

Current Allergic Rhinoconjunctivitis Treatment Landscape

According to established treatment guidelines, allergic rhinoconjunctivitis management follows a stepwise approach encompassing allergen avoidance, pharmacological interventions, and immunotherapy Pharmacological treatments primarily consisting of first-line medications such as intranasal corticosteroids (INCS), second-generation oral and nasal antihistamines, and oral leukotriene receptor antagonists (LTRA), while second-line medications include oral corticosteroids, mast cell stabilizers, nasal decongestants, and nasal anticholinergics. The updated ARIA-EAACI 2024-2025 guidelines - based on the GRADE evidence-to-decision framework - issued recommendations prioritizing the choice between intranasal INCS, INAH, and fixed combinations of INAH + INCS, with INCS recommended as the most efficacious intranasal treatment class for moderate-to-severe persistent allergic rhinoconjunctivitis. For ocular symptoms, oral antihistamines including desloratadine, fexofenadine, loratadine, olopatadine, and rupatadine demonstrated the highest probability of improving rhinoconjunctivitis-related quality of life in seasonal allergic rhinoconjunctivitis, while the ARIA-EAACI 2024-2025 guidelines recommend oral antihistamines over LTRA and ocular antihistamines over mast cell stabilisers for conjunctival symptoms. Allergen Immunotherapy (AIT) - delivered via subcutaneous (SCIT) or sublingual (SLIT) routes - is the only disease-modifying treatment option for allergic rhinoconjunctivitis, recommended for patients who remain symptomatic despite pharmacotherapy or those in whom prevention of asthma development is a priority, particularly in pediatric populations.

Allergic Rhinoconjunctivitis Epidemiology

The epidemiology section of the allergic rhinoconjunctivitis market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report. This section also presents the data with relevant tables and graphs, offering a clear and concise view of the prevalence of allergic rhinoconjunctivitis. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.

Key Findings

• As per secondary analysis, the prevalence of the allergic rhinoconjunctivitis estimated to be 30% of the population, and more prevalent in younger individuals.
• Based on a large international study, adolescents aged 13-14 years across 25 countries found that 13.3% reported experiencing symptoms of rhinoconjunctivitis, while among children aged 6-7 years from 16 countries, 7.7% were found to suffer from current rhinoconjunctivitis symptoms - reflecting a significant disease burden even among younger age groups across the 7MM.
• Recent longitudinal analyses in the UK shows that allergic rhinoconjunctivitis impacts approximately 1 in 8 adults and 1 in 14 children, with prevalence rates notably rising in the adult population.
• Major risk factors contributing to regional differences in allergic rhinoconjunctivitis prevalence across the 7MM include genetic predisposition, exposure to pollen and dust mite allergens, air pollution, smoking, urban living, and climate change. The epidemiology of Allergic Rhinoconjunctivitis is expected to change during the forecast period (2026-2036).

Allergic Rhinoconjunctivitis Market Outlook

The allergic rhinoconjunctivitis therapeutics market is further expected to increase by the major drivers, such as the rising prevalence population, technological advancements, and upcoming therapies in the forecast period (2026-2036).

With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to DelveInsight, the allergic rhinoconjunctivitis market in the 7MM is expected to change significantly during the forecast period 2026-2036.

Allergic Rhinoconjunctivitis Drug Analysis & Competitive Landscape

The allergic rhinoconjunctivitis drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I-III clinical trials. It covers mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, strategic partnerships upcoming key catalyst for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the allergic rhinoconjunctivitis treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the allergic rhinoconjunctivitis therapeutics market.

Approved Therapies for Allergic Rhinoconjunctivitis

Mixed Pollens Allergen Extract (ORALAIR): Stallergenes Greer

Mixed Pollens Allergen Extract (ORALAIR), developed by Stallergenes Greer, is a sublingual allergen immunotherapy tablet containing extracts from five grass pollens (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass). It is indicated for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis in patients aged 5 years and older and is designed to induce long-term immune tolerance through repeated allergen exposure.

• First authorized for use in Europe in 2009, ORALAIR subsequently received US FDA approval in April 2014 for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis. In November 2018, the FDA expanded its indication to include pediatric patients aged 5 through 17 years, making ORALAIR one of the first grass pollen allergen immunotherapy tablets available for both adult and pediatric populations and further advancing disease-modifying treatment options beyond conventional symptomatic pharmacotherapy for allergic rhinoconjunctivitis.

House Dust Mite Allergen Extract (ODACTRA): ALK-Abello

House Dust Mite Allergen Extract (ODACTRA), developed by ALK, is a sublingual allergen immunotherapy tablet containing standardized extracts of the house dust mites Dermatophagoides farinae and Dermatophagoides pteronyssinus. It is indicated for the treatment of house dust mite-induced allergic rhinitis with or without conjunctivitis and is designed to induce long-term immune tolerance by modifying the underlying allergic response rather than providing symptomatic relief alone.

• In February 2025, the FDA expanded its indication to include children aged 5-11 years, broadening the eligible patient population and reinforcing ODACTRA's position as a leading disease-modifying immunotherapy option for both pediatric and adult patients with allergic rhinoconjunctivitis.
• First approved in Japan in 2015 as one of the earliest house dust mite allergen immunotherapy tablets, ODACTRA subsequently received approvals in Europe under the brand name ACARIZAX and was approved by the US FDA in March 2017 for the treatment of house dust mite-induced allergic rhinitis, with or without conjunctivitis.

Allergic Rhinoconjunctivitis Pipeline Analysis

The allergic rhinoconjunctivitis market is expected to evolve gradually, driven by a growing number of emerging therapies currently in clinical development. Key players such as Inmunotek (MM09-MG01), among others, are showing active commitment to addressing this unmet need, with ongoing efforts to advance novel treatment options for this complex and heterogeneous allergic condition.

MM09-MG01: Inmunotek

MM09-MG01, developed by Inmunotek, is a subcutaneously administered allergen immunotherapy product containing biological extracts of house dust mite (Dermatophagoides pteronyssinus and/or D. farinae), currently being evaluated in a Phase III prospective, randomized, placebo-controlled, multicenter trial assessing efficacy and safety of subcutaneous immunotherapy in patients with mild to moderate asthma and allergic rhinitis/rhinoconjunctivitis due to hypersensitivity to house dust mites.

Allergic Rhinoconjunctivitis Market Segmentation

DelveInsight's 'Allergic Rhinoconjunctivitis - Market Insights, Epidemiology, and Market Forecast - 2036 report provides a detailed outlook of the current and future allergic rhinoconjunctivitis market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.

Allergic Rhinoconjunctivitis Market Size by Countries

The allergic rhinoconjunctivitis market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2025, the United States held a significant share of the overall 7MM (Seven Major Markets) allergic rhinoconjunctivitis market, primarily attributed to the country's higher diagnosed prevalence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.

Allergic Rhinoconjunctivitis Drugs Uptake

This section focuses on the sales uptake of potential of allergic rhinoconjunctivitis drugs that have recently been launched or are anticipated to be launched in the allergic rhinoconjunctivitis market between 2022 and 2036. It estimates the market penetration of allergic rhinoconjunctivitis drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the allergic rhinoconjunctivitis market.

The emerging allergic rhinoconjunctivitis therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the allergic rhinoconjunctivitis market.

Allergic Rhinoconjunctivitis Market Access and Reimbursement

DelveInsight's 'Allergic Rhinoconjunctivitis - Market Insights, Epidemiology, and Market Forecast - 2036' report provides a descriptive overview of the market access and reimbursement scenario of allergic rhinoconjunctivitis.

This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.

KOL Views

To keep up with current allergic rhinoconjunctivitis market trends and fill gaps in secondary findings, we interview KOLs and SMEs' working in allergic rhinoconjunctivitis domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or allergic rhinoconjunctivitis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the allergic rhinoconjunctivitis unmet needs.

Allergic Rhinoconjunctivitis: KOL Insights

DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as National Jewish Health, Charite - Universitatsmedizin Berlin, Hospital Clinic de Barcelona, Humanitas Research Hospital, Hopital Europeen Georges-Pompidou, Royal Brompton Hospital, and Jikei University Hospital among others.

Competitive Intelligence Analysis

We conduct a Competitive and Market Intelligence analysis of the allergic rhinoconjunctivitis market, utilizing various Competitive Intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.

Allergic Rhinoconjunctivitis Pipeline Development Activities

The report offers an analysis of therapeutic candidates in Phase I/II and III stages and examines companies involved in developing targeted therapeutics for allergic rhinoconjunctivitis. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.

Pipeline Development Activities

The report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging allergic rhinoconjunctivitis therapies.

Allergic Rhinoconjunctivitis Report Insights

• Allergic Rhinoconjunctivitis Patient Population
• Therapeutic Approaches
• Allergic Rhinoconjunctivitis Pipeline Analysis
• Allergic Rhinoconjunctivitis Market Size and Trends
• Allergic Rhinoconjunctivitis Market Opportunities
• Impact of Upcoming Therapies

Allergic Rhinoconjunctivitis Report Key Strengths

• 11 Years Forecast
• The 7MM Coverage
• Allergic Rhinoconjunctivitis Epidemiology Segmentation
• Competitive Landscape
• Highly Analyzed Allergic Rhinoconjunctivitis Market
• Allergic Rhinoconjunctivitis Drugs Uptake

Allergic Rhinoconjunctivitis Report Assessment

• Allergic Rhinoconjunctivitis Current Treatment Practices
• Unmet Needs
• Allergic Rhinoconjunctivitis Pipeline Product Profiles
• Allergic Rhinoconjunctivitis Market Attractiveness

Key Questions:

• How common is allergic rhinoconjunctivitis?
• What are the key findings of allergic rhinoconjunctivitis epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2022-2036)?
• What are the currently available treatments for allergic rhinoconjunctivitis?
• What are the disease risk, burden, and unmet needs of allergic rhinoconjunctivitis?
• At what CAGR is the allergic rhinoconjunctivitis market and its epidemiology is expected to grow in the 7MM during the forecast period (2026-2036)?
• How would the unmet needs impact the allergic rhinoconjunctivitis market dynamics and subsequently influence the analysis of the related trends?
• What would be the forecasted patient pool of allergic rhinoconjunctivitis in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2026-2036)?
• How many companies are currently developing therapies for the treatment of allergic rhinoconjunctivitis?

Reasons to buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the allergic rhinoconjunctivitis market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of current treatment in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the attribute analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Frequently Asked Questions:

1. What are the treatment goals for allergic rhinoconjunctivitis?

The primary goals in the treatment of allergic rhinoconjunctivitis are to achieve effective control of nasal and ocular symptoms, minimize the impact of the disease on daily activities, sleep, school and work productivity, reduce the risk of exacerbations and associated allergic comorbidities such as asthma, and improve overall quality of life. Treatment strategies focus on allergen avoidance where feasible, symptomatic relief through pharmacotherapy, and long-term disease modification through allergen immunotherapy in appropriately selected patients.

2. What are the challenges in managing allergic rhinoconjunctivitis?

Managing allergic rhinoconjunctivitis remains challenging due to its chronic and recurrent nature, variability in symptom severity, and frequent coexistence with other atopic conditions such as asthma and atopic dermatitis. Many patients continue to experience inadequate symptom control despite available therapies, while adherence to long-term treatment regimens and allergen immunotherapy can be suboptimal. Additional challenges include ongoing environmental and seasonal allergen exposure, regional variability in access to specialist care and immunotherapy, and the lack of universally effective therapies capable of providing both rapid symptom relief and sustained disease modification.

3. What are the key factors driving the growth of the allergic rhinoconjunctivitis market?

The allergic rhinoconjunctivitis market is being driven by the increasing prevalence of allergic diseases, rising environmental and pollen exposure associated with urbanization and climate-related changes, growing awareness and diagnosis rates, and expanding use of allergen immunotherapy. Continued innovation in intranasal combination therapies, biologic agents targeting allergic inflammation, and next-generation immunotherapy platforms is further supporting market growth. Additionally, increasing emphasis on personalized allergy management and improved treatment accessibility is expected to contribute to continued market expansion.

4. How will the allergic rhinoconjunctivitis Market and Epidemiology Forecast Report benefit the clients?

The report provides comprehensive insights into the allergic rhinoconjunctivitis market, including epidemiological trends across the 7MM, current treatment practices, approved and emerging therapies, competitive landscape, regulatory developments, and unmet needs. These insights support strategic decision-making, business development, market opportunity assessment, competitive benchmarking, and commercialization planning for stakeholders operating across the allergy, immunology, respiratory, and ophthalmology sectors.